Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.60 |
| ▸ | CTSD | P07339 | 16/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753060 | 0.86 | BACE1 (0.73) | BACE1CTSDCYP3A4 | |
| SCHEMBL1938564 | 0.86 | BACE1 (0.59) | BACE1CTSDCYP3A4 | |
| SCHEMBL4701357 | 0.85 | BACE1 (0.83) | BACE1CTSDCYP3A4 | |
| SCHEMBL14498131 | 0.85 | BACE1 (0.71) | BACE1CTSDCYP3A4 | |
| Hydrochloric Acid SCHEMBL3012802 | 0.85 | BACE1 (0.58) | BACE1CTSDCYP3A4 | |
| SCHEMBL2877502 | 0.84 | BACE1 (0.73) | BACE1CTSD | |
| SCHEMBL8281586 | 0.84 | BACE1 (0.73) | BACE1CTSD | |
| Hydrochloric Acid SCHEMBL2875561 | 0.83 | BACE1 (0.72) | BACE1CTSD | |
| Methylamine SCHEMBL5736229 | 0.83 | BACE1 (0.72) | BACE1CTSD | |
| SCHEMBL5579048 | 0.83 | BACE1 (0.58) | BACE1CTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | BACE1 5/4885CTSD 51/4885CYP3A4 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.